IDEXX Laboratories (NASDAQ:IDXX) PT Raised to $630.00 at JPMorgan Chase & Co.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) had its price objective boosted by equities researchers at JPMorgan Chase & Co. from $600.00 to $630.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 11.76% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Barclays upped their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday. The Goldman Sachs Group boosted their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a research report on Tuesday, January 30th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $500.00 to $460.00 and set a “hold” rating on the stock in a research report on Monday, October 30th. Finally, StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, December 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $591.50.

View Our Latest Stock Analysis on IDXX

IDEXX Laboratories Price Performance

NASDAQ IDXX traded down $8.42 during trading hours on Tuesday, reaching $563.70. The company’s stock had a trading volume of 265,990 shares, compared to its average volume of 475,728. The firm’s 50-day moving average price is $532.94 and its 200-day moving average price is $490.47. The company has a quick ratio of 1.02, a current ratio of 1.43 and a debt-to-equity ratio of 0.48. IDEXX Laboratories has a 1 year low of $372.50 and a 1 year high of $579.68. The company has a market capitalization of $46.82 billion, a price-to-earnings ratio of 57.48, a PEG ratio of 2.92 and a beta of 1.25.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a return on equity of 85.68% and a net margin of 22.93%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.05 EPS. On average, equities research analysts predict that IDEXX Laboratories will post 9.87 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jonathan Jay Mazelsky sold 7,128 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $513.05, for a total transaction of $3,657,020.40. Following the completion of the sale, the chief executive officer now directly owns 79,233 shares in the company, valued at approximately $40,650,490.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other IDEXX Laboratories news, EVP James F. Polewaczyk sold 11,636 shares of the stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $521.79, for a total value of $6,071,548.44. Following the completion of the sale, the executive vice president now directly owns 10,050 shares in the company, valued at $5,243,989.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jonathan Jay Mazelsky sold 7,128 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $513.05, for a total value of $3,657,020.40. Following the completion of the sale, the chief executive officer now owns 79,233 shares of the company’s stock, valued at $40,650,490.65. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On IDEXX Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDXX. Panagora Asset Management Inc. increased its holdings in shares of IDEXX Laboratories by 50.3% in the first quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company’s stock valued at $1,768,000 after purchasing an additional 1,081 shares during the period. Raymond James Trust N.A. increased its holdings in shares of IDEXX Laboratories by 26.8% in the first quarter. Raymond James Trust N.A. now owns 1,624 shares of the company’s stock valued at $888,000 after purchasing an additional 343 shares during the period. Cetera Investment Advisers increased its holdings in shares of IDEXX Laboratories by 77.1% in the first quarter. Cetera Investment Advisers now owns 3,675 shares of the company’s stock valued at $2,010,000 after purchasing an additional 1,600 shares during the period. Moors & Cabot Inc. increased its holdings in shares of IDEXX Laboratories by 3.0% in the first quarter. Moors & Cabot Inc. now owns 1,757 shares of the company’s stock valued at $961,000 after purchasing an additional 52 shares during the period. Finally, Sequoia Financial Advisors LLC increased its holdings in shares of IDEXX Laboratories by 15.6% in the first quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company’s stock valued at $543,000 after purchasing an additional 134 shares during the period. 86.85% of the stock is currently owned by hedge funds and other institutional investors.

About IDEXX Laboratories

(Get Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Read More

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.